This Introduction to Part B complements the Introduction to this Annex with points which are specific for active substances that are micro-organisms.
For the purpose of Part B, the following definitions apply:
‘strain’ means a genetic variant of an organism in its taxonomic level (species) that is made up of the descendants of a single isolation in pure culture from the original matrix (e.g. the environment) and usually is made up of a succession of cultures ultimately derived from an initial single colony;
‘colony-forming unit’ (‘CFU’) means a measurement unit used to estimate the number of bacterial or fungal cells in a sample, which have the ability to multiply under controlled growing conditions, with the consequence that one or more cells reproduce and multiply to form a single visible colony;
‘International Unit’ (‘IU’) means a quantity of a substance that produces a specific effect when tested in accordance with an internationally accepted biological procedure;
‘Microbial Pest Control Agent as manufactured’ (‘MPCA as manufactured’) means the outcome of the manufacturing process of the micro-organism(s) intended to be used as active substance in plant protection products, consisting of the micro-organism(s) and any additives, metabolites (including metabolites of concern), chemical impurities (including relevant impurities), contaminating micro-organisms (including relevant contaminating micro-organisms) and the spent medium/rest fraction resulting from the manufacturing process or, in case of a continuous manufacturing processes where a strict separation between the manufacturing of the micro-organism(s) and the production process of the plant protection product is not possible, a non-isolated intermediate;
‘additive’ means a component added to the active substance during its manufacturing, to preserve microbial stability and/or facilitate handling;
‘purity’ means the content of the micro-organism present in the MPCA as manufactured expressed in a relevant unit and the maximum content of substances of concern in case they are identified;
‘relevant contaminating micro-organism’ means a pathogenic/infective micro-organism unintentionally present in the MPCA as manufactured;
‘seed stock’ means a microbial strain starter culture used to manufacture the MPCA as manufactured or the final plant protection product;
‘spent medium/rest fraction’ means the fraction of the MPCA as manufactured consisting of remaining or transformed starting materials, and excluding the micro-organism(s) that is the active substance, metabolites of concern, additives, relevant contaminating micro-organisms, and relevant impurities;
‘starting material’ means substances used in the manufacturing process of the MPCA as manufactured as substrate and/or buffering agent;
‘ecological niche’ means an ecological function and actual physical spaces occupied by a particular species within the community or ecosystem;
‘host range’ means the range of different biological host-species that can be infected by a microbial species or strain;
‘infectivity’ means the ability of a micro-organism to cause an infection;
‘infection’ means the non-opportunistic introduction or entry of a micro-organism into a susceptible host, where the micro-organism is able to reproduce to form new infective units and persist in the host, whether or not the micro-organism causes pathological effects or disease;
‘pathogenicity’ means the non-opportunistic ability of a micro-organism to inflict injury and damage to the host upon infection;
‘non-opportunistic’ means a condition under which a micro-organism exerts an infection or inflicts an injury or damage when the host is not weakened by a predisposing factor (e.g. immune system impaired by an unrelated cause);
‘opportunistic infection’ means an infection occurring in a host weakened by a predisposing factor (e.g. immune system impaired by an unrelated cause);
‘virulence’ means the degree of pathogenicity that a pathogenic micro-organism is able to exert in the host;
‘virulence factor’ means a factor that enhance the pathogenicity/virulence of a micro-organism;
‘metabolite of concern’ means a metabolite produced by the micro-organism under assessment, with known toxicity or known relevant antimicrobial activity, which is present in the MPCA as manufactured at levels that may present a risk to human health, animal health or the environment, and/or for which it cannot be adequately justified that in-situ production of the metabolite is not relevant for the risk assessment;
‘in-situ production’ means the production of a metabolite by the micro-organism after application of the plant protection product containing that micro-organism;
‘background level of a metabolite’ means a level of a metabolite that is likely to occur in relevant European environments (including also sources different than those of plant protection) and/or in food and feed (e.g. edible plant parts), when the micro-organisms are in conditions to grow, reproduce and to produce such metabolite in presence of a host or availability of carbon and nutrient sources, under consideration of high host densities and nutrients;
‘antimicrobial resistance’ (‘AMR’) means the intrinsic or acquired ability of a micro-organism to multiply in the presence of an antimicrobial agent at concentrations which are relevant for therapeutic measures in human or veterinary medicine, making that substance therapeutically ineffective;
‘antimicrobial agent’ means any antibacterial, antiviral, antifungal, anthelmintic or antiprotozoal agent that is a substance of natural, semi-synthetic, or synthetic origin that at in vivo concentrations kills or inhibits the growth of micro-organisms by interacting with a specific target;
‘acquired antimicrobial resistance’ means a non-intrinsic and acquired novel resistance enabling a micro-organism to survive or multiply in the presence of an antimicrobial agent at concentrations higher than that which inhibits wild type strains of the same species;
‘intrinsic antimicrobial resistance’ means all inherent properties of a microbial species that limit the action of antimicrobial agents thereby allowing it to survive and multiply in presence of the antimicrobial agents at concentrations that are relevant for their therapeutic uses. Inherent properties of micro-organisms are considered not transferable and can include structural characteristics like lack of drug targets, the impermeability of cellular envelopes, activity of multidrug efflux pumps, or activity of metabolic enzymes. An antimicrobial resistance gene is considered intrinsic if it is located on a chromosome in the absence of mobile genetic element and shared by the majority of wild type strains of the same species;
‘relevant antimicrobial activity’ means the antimicrobial activity caused by relevant antimicrobial agents;
‘relevant antimicrobial agents’ means all antimicrobial agents important for therapeutic use in humans or animals, as described in the latest available versions at the time of submission of the dossier:
in a list adopted by means of Commission Regulation (EU) 2021/1760 [Commission Delegated Regulation (EU) 2021/1760 of 26 May 2021 supplementing Regulation (EU) 2019/6 of the European Parliament and of the Council by establishing the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans (OJ L 353, 6.10.2021, p. 1).] in accordance with Article 37(5) of Regulation (EU) 2019/6 of the European Parliament and of the Council [Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (OJ L 4, 7. 1.2019, p.43).], or
by the World Health Organisation [https://www.who.int/publications/i/item/9789241515528.] in the lists of Critically Important Antimicrobials, Highly Important Antimicrobials and Important Antimicrobials for Human Medicine;
‘viroid’ means any of a class of infectious agents consisting of a small strand of RNA not associated with any protein. The RNA does not code for proteins and is not translated; it is replicated by host cell enzymes;
‘predicted environmental density’ means a conservative estimation of the population density of the micro-organism in soil or surface water upon application in accordance with the conditions of use, calculated based on the maximum application rate and the maximum number of applications per year of the plant protection product containing the micro-organism.
The information from scientific peer-reviewed literature as provided for under point 1.4 of the Introduction shall be provided at the relevant taxonomic level of the micro-organism (e.g. strain, species, genus). An explanation on why the chosen taxonomic level is considered relevant for the addressed data requirement shall be provided.
Other available sources of information, such as medical reports, may also be provided and submitted in a summary.
Where appropriate or specifically indicated in the data requirements, test guidelines as described in Part A shall be used also for this Part, upon adaptation in such a way that they are appropriate for chemical compounds present in the MPCA as manufactured.
Where testing is done, a detailed description (specification) of the material used and its impurities, in accordance with point 1.4, shall be provided. Where studies are conducted using micro-organisms produced in the laboratory or in a pilot scale production system, the studies shall be repeated using the MPCA as manufactured, unless it can be demonstrated that the test material used is essentially the same for the purposes of the testing and assessment.
If the active substance is a genetically modified micro-organism, a copy of the evaluation of the data concerning the risk assessment, as stated in Article 48 of Regulation (EC) No 1107/2009, shall be submitted.
The assessment of pathogenicity and infectivity of micro-organisms shall be based on a weight of evidence approach, taking into account that:
tests on animals may not always be suitable for extrapolation to humans due to differences between humans and test animals (e.g. immune system, microbiome), and
micro-organisms might have narrow host range, as a result of which it cannot always be assumed that a micro-organism that does not cause disease in the animals tested has the same result in humans, and vice-versa.
The information on the micro-organism shall be sufficient to permit an evaluation to be made as to the risk concerning to anti-microbial resistance.
Until validated methods for testing dermal and respiratory sensitisation caused by micro-organisms become available, all micro-organisms shall be considered as potential sensitisers.
The name and address of the applicant shall be provided, as well as the name, address, telephone number and e-mail address of a contact point.
The following information shall be provided:
the name and address of the producer of the active substance;
the name and address of each manufacturing plant in which the active substance is produced or will be produced;
a contact point (preferably a central contact point), including name, telephone number and e-mail address.
Where, following approval of the micro-organism, there are changes in the address or number of producers, the information required shall again be submitted.
The information provided shall allow an unambiguous identification and characterisation of the micro-organism.
The micro-organism shall be deposited at an internationally recognised culture collection at the time of submission of the dossier. The contact details of the culture collection and accession number shall be submitted.
The micro-organism shall be identified as unequivocally belonging to a certain species, based on the latest scientific information, and named at strain level, including any other designation which may be relevant to the micro-organism (e.g. isolate level, if relevant for viruses). Its scientific name and taxonomic grouping shall be stated. This includes traditional Linnean taxonomy (kingdom, phylum, class, order, family, genus, species, and strain) as well as established rank-free phylogenetic taxa in between these Linnean ranks and any other denomination relevant to the micro-organism (e.g. serovar, pathovar, biovar).
All known synonymous, alternative, superseded names shall be provided. If code names have been used during development these shall also be provided.
A phylogenetic tree including the micro-organism shall be provided. The scale of the phylogenetic tree shall be selected to include relevant strains and species (e.g. in case of use of read-across among related strains or species to address data requirements). Superseded names of included micro-organisms or taxonomic groupings may be indicated in the phylogenetic tree.
It shall be indicated whether the micro-organism is a wild type, a mutant (either spontaneous or induced) or whether it has been genetically modified. If the micro-organism is a mutant or has been modified, all known differences in properties, including genetic differences, between the modified micro-organism and the parent wild strain shall be provided. The technique used for the modification shall be reported.
The minimum and maximum content of the micro-organism in the MPCA as manufactured shall be derived from the analysis of five representative batches as indicated under point 1.4.3 and reported. The content shall be expressed in appropriate microbial unit that most accurately reflects plant protection action, such as number of active units, colony forming units, or international units per volume or weight or any other manner that is relevant to the risk assessment on the micro-organism. A rationale for the relevance of the microbial unit used in the context of the tests to be conducted shall be provided. The use of such unit shall be consistent along studies and literature data provided. In case of provision of literature data with different units, recalculation based on the units used shall be provided.
In case it is claimed that one or more metabolites present in the MPCA as manufactured are part of the plant protection action, the content of these metabolites shall be indicated as provided for in point 1.9 of Part A.
Data on additives, relevant contaminating micro-organisms, relevant impurities and metabolites of concern, present in the MPCA as manufactured shall be directly derived from the analysis of five representative batches as indicated under point 1.4.3 and reported.
The identity, minimum and maximum content in g/kg of each additive in the MPCA as manufactured shall be provided.
The identity and maximum content of relevant contaminating micro-organisms in the MPCA as manufactured, expressed in the appropriate unit, shall be reported.
The identity and maximum content of chemical impurities present in the MPCA as manufactured and which are relevant due to undesirable toxicological, ecotoxicological or environmental properties, shall be reported in g/kg, including also metabolites of concern produced by the micro-organism as impurities in the manufacturing batch.
At least five representative batches from recent and current production of the micro-organism shall be analysed. All of the representative batches shall bear a date within the last five years of manufacture. Manufacturing dates of the representative batches and batches size shall be reported.
Where the active substance is produced in different manufacturing plants, the information required under this point shall be provided for each of the plants separately.
Where the information provided relates to a pilot manufacturing plant production system, the information required shall again be provided once industrial scale production methods and procedures have stabilised. Where available, industrial scale data shall be provided before approval under Regulation (EC) No 1107/2009. Where data on industrial scale production are not available, a justification shall be provided.
Information on how the micro-organism is produced in bulk shall be provided for all the steps of the manufacturing process. Such information shall include relevant descriptions of:
starting materials,
culture media sterilisation (e.g. autoclave),
initial inocula level for the culture media (e.g. number of conidia/g of dry culture media),
cultures and media conditions (e.g. pH, temperature, water activity (aw)),
phase of the growth curve and growth stage of the micro-organism during the production process,
ratio vegetative cells / (endo)spores,
fermentation process,
purification and cellular dehydration,
other technical parameters (e.g. centrifugation protocols).
The type of manufacturing process (e.g. continuous or batch process) shall be indicated.
Both production method/process and product shall be subject to a continuous quality control, and the quality assurance criteria shall be submitted. In particular, the possible occurrence of spontaneous changes of characteristics of the micro-organism shall be monitored. It shall be indicated where in the process the quality assurance steps are implemented and it shall be described how the samples for quality assurance screening are taken.
The techniques used to ensure a uniform product, and the assay methods for its standardisation, maintenance and purity, to prevent the presence of relevant contaminating micro-organisms and relevant impurities in the MPCA as manufactured shall be described and specified.
Information on possible loss of activity of starting cultures shall be provided along with corresponding methods to assess it. If relevant, any method aiming at preventing the micro-organism from losing its effects on the target organism shall be described.
A safety data sheet pursuant to Article 31 of Regulation (EC) No 1907/2006 [Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ L 396, 30.12.2006, p. 1).] shall be provided for the MPCA as manufactured.
Methods to dispose safely of the MPCA as manufactured or, where necessary, to render the micro-organism non-viable prior to disposal of the MPCA as manufactured (e.g. chemical methods or autoclaving) and methods to dispose of contaminated packaging and other materials shall be described.
Information that makes it possible to establish the effectiveness and safety of these methods shall be provided.
The geographical location and environmental compartment (e.g. substrate, host organisms), from which the micro-organism was isolated, shall be stated. The method of isolation and the selection procedure of the micro-organism shall be reported.
The geographical distribution of the micro-organism shall be described.
The environmental compartment(s) where the micro-organism is already expected to occur shall be described (e.g. soil, water, rhizosphere, phyllosphere, host organism).
When relevant, food or feed commodities where the micro-organism is already expected to occur shall be described.
The information referred to in this point shall be provided at the most relevant highest taxonomic level (e.g. strain, species, genus) and the choice of the relevant highest taxonomic level shall be justified.
Previous and current known uses of the micro-organism (e.g. research, commercial, uses evaluated for recommending the Qualified Presumption of Safety [https://www.efsa.europa.eu/en/topics/topic/qualified-presumption-safety-qps.] status) shall be described. The description shall include both plant protection and other uses (e.g. uses and/or assessments under other regulatory frameworks, bioremediation, uses in food and feed).
The information referred to in this point shall be provided at the most relevant highest taxonomic level (e.g. strain, species, genus). The choice of the relevant highest taxonomic level shall be justified.
The known life cycle(s) of the micro-organism, its lifestyle(s) (e.g. parasitic, saprophytic, endophytic, pathogenic) and its ecological niche(s) shall be described, along with all forms that may occur and the type of reproduction.
For bacteriophages, information shall be provided on, if applicable, lysogenic and lytic properties.
For fungi and bacteria, information shall be provided, if applicable, on:
external conditions for resting stages, information on resistance of spores against adverse environmental conditions, survival time of the spores and conditions for germination, and/or
formation of biofilm.
All available information on modes of action against the target organism(s) shall be provided.
In case of a pathogenic or parasitic mode of action on the target organism, information on the site of infection and mode of entry into the target organism, the infective dose and the susceptible stages of the target organism shall be given. The results of any experimental studies shall be reported.
In case of a mode of action based on a metabolite of concern produced by the micro-organism under assessment and identified as required by point 2.8, information from scientific peer-reviewed literature or any other reliable source on likely mode of action of the metabolite of concern and likely exposure route of the target organism to the metabolite of concern shall be provided.
All known host organisms of the micro-organism shall be listed at the relevant taxonomic level. Available information on possible density of host organisms, supporting the indication on natural occurrence of the micro-organisms, shall be provided.
The conditions required for growth and proliferation of the micro-organism shall be described (e.g. host, nutrients, pH, osmotic potential, humidity). The minimum, optimum and maximum temperature required for growth and proliferation shall be reported. The generation time under favourable growth conditions shall be reported.
In case any pathogenic mode(s) of action on the target organism is described under point 2.3, virulence factors and (if applicable) environmental factors affecting them shall be indicated and described. The results of any relevant experimental studies and/or data/information from the existing literature at the relevant taxonomic level shall be reported.